Top Injectable Manufacturer in Trinidad and Tobago – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 1 day ago
- 12 min read
Last Updated: September 5, 2026
TL;DR: Trinidad and Tobago answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with three layered lists, India on none of them, and Indian factories nonetheless the largest source of the medicines it registers and buys. The Food and Drugs Regulations of 1964 name Canada, the United States, the United Kingdom and Australia plus a ministerial-discretion clause; the Chemistry, Food and Drugs Division's notice of 4 November 2022 names the WHO's stringent authorities for biologics and, for small molecules and generics, six PAHO level-4 authorities, the EU-27 and the UK, as the sources of the CPP it relies on 'to expedite'; the Caribbean Regulatory System in Port of Spain relies on PAHO reference authorities, ICH and WHO level-3 agencies, or WHO prequalification. CDSCO's own level-3 listing is for vaccines only. The gate is a certificate-origin test — an apostilled CPP from a listed authority, an Indian GMP certificate, Zone IVb stability, three samples, TT$750 and a 120-day clock — and India tops the register every year from 2022 to 2025 and supplies about three fifths of NIPDEC's 2025–26 injectable award lines. Since 4 July 2025 the country also recognises the Indian Pharmacopoeia: a standards opening, not regulatory reliance.
Key Takeaways
Three lists, kept apart, and India on none. The Regulations: a certificate from Canada, the US FDA, the UK or Australia, or from a body the Minister considers adequate. The CFDD notice of November 2022: EMA, US FDA, Health Canada, Swissmedic, Medsafe, TGA and MHRA for biologics; ANMAT, ANVISA, CECMED, INVIMA, COFEPRIS and ISP, the EU-27 and the UK for small molecules and generics. The CRS guidance of November 2020: PAHO reference authorities plus ICH and WHO level-3 agencies, or WHO prequalification. What happens to a CPP from an unlisted authority is stated nowhere.
The mechanics are old and cheap. The Food and Drugs Act, Chapter 30:01 of 1960, last amended in 2005 and not superseded, requires a Form C submission in four sections rather than CTD, electronic since November 2022, with an apostilled CPP, a GMP certificate from the manufacturing country's regulator — for an Indian site, the Indian one — Zone IVb stability on three lots, three finished samples, TT$750 and a statutory decision within 120 days. No validity period or renewal was found. Injectable antibiotics fall under a separate Antibiotics Act we did not read.
India is already the largest supplier. On the CFDD register India is the leading country of origin in every year from 2022 to 2025; on the CRS registry Indian marketing-authorisation holders account for the largest share of roughly 337 recommendations; and in NIPDEC's 2025–26 award list of 1,458 lines about 48% of all lines and about 59% of the 409 injectable lines are Indian-made, by our approximate count. Which certificate each product used is not visible, so we do not say Trinidad and Tobago relies on CDSCO — only that the certificate-origin gate has not kept Indian injectables out.
The buyer is NIPDEC, and it is under pressure. A National Insurance Board subsidiary contracted since 1993 to run the health supply chain for the Ministry of Health and five regional health authorities, and since 2003 the Chronic Disease Assistance Programme — fifty-one items through 275 private pharmacies on one NIPDEC page, fifty-three through about 257 on another — buying under the Public Procurement and Disposal of Public Property Act 2015. Out-of-pocket payments were 45.3% of health spending in 2023, adult diabetes prevalence 12.4% in 2024, and press reports of programme shortages in May 2026 cite supplier-payment delays — reported, not verified.
Introduction: Why Trinidad and Tobago Demands a Premium Injectable Manufacturer in Trinidad and Tobago
Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Trinidad and Tobago is the first market in the series to answer with three lists at once, and the discipline is to keep them apart. The oldest is statutory: Division 3 of the Second Schedule to the Food and Drugs Regulations, made under the Food and Drugs Act, Chapter 30:01, requires a new-drug submission for an imported medicine to include a Canadian notice of compliance, a US FDA certificate, a certificate from the UK or Australian health authorities, or a certificate in English from an official body 'considered by the Minister as adequate', with a further paragraph allowing the Minister to accept detailed safety reports instead. The second is administrative: the Chemistry, Food and Drugs Division's notice to importers of 4 November 2022 tells applicants where to obtain the certificate of pharmaceutical product — for biologics, from the WHO's stringent regulatory authorities; for small molecules and generics, from the six PAHO level-4 authorities of Argentina, Brazil, Cuba, Colombia, Mexico and Chile, the twenty-seven EU member states and the UK — and adds in a footnote that the Division relies on previous approval by those authorities 'to expedite the approval process'. The third is regional: the Caribbean Regulatory System, run by CARPHA from Port of Spain, whose guidance of November 2020 lists PAHO reference authorities and ICH or WHO level-3 agencies, and admits WHO-prequalified products by a second pathway.
India's CDSCO is on none of the three, and its own place on the WHO's August 2026 maturity list is at level 3 for vaccines only, so the CRS's level-3 clause does not reach an Indian small-molecule injectable. What the lists do not say matters as much. The 2022 notice defines a reference authority as the country from which the CPP was issued, so the gate is a certificate-origin test layered on an agency list; it does not state what happens to a CPP from an unlisted authority, and we found no text that refuses one, nor any that accepts one. Beside the CPP, the Division's detailed requirements ask for a GMP certificate 'issued by the drug regulatory authority of the manufacturing country' — for an Indian site, the Indian certificate — and the Act's own border rule requires every imported drug to conform to the law of the country where it was made and to carry that country's official certificate. A premium injectable manufacturer in Trinidad and Tobago is therefore one that holds a listed-authority CPP or WHO prequalification for the product, an Indian GMP certificate for the site, and a dossier written for a 120-day statutory clock.
What Sets a World-Class Injectable Manufacturer in Trinidad and Tobago Apart
The paradox that sets this market apart is that the lists have not kept India out. The Division's own register of drugs approved from 1999 to 2025, published in December 2025, shows India as the leading country of origin in every year from 2022 to 2025 — by our approximate count of entry lines, 157 of 476 in 2025 — and the entries made after the November 2022 notice include sterile injectables from Aspiro, Venus Remedies, Troikaa, Zydus Hospira, Caplin Point, Gland Pharma, Divine Laboratories, TherDose and Emcure. The CRS registry, queried in September 2026, returned roughly 337 recommendations, roughly 214 of them active, and Indian marketing-authorisation holders dominate it — Hetero, Intas, Macleods, Venus, Troikaa and Aculife among them — with active injectables including midazolam, bupivacaine, propofol, dopamine, irinotecan and piperacillin-tazobactam. By the CRS's rules each of those rested on a listed reference-authority registration or on WHO prequalification, and neither register shows which; we therefore do not say that Trinidad and Tobago relies on CDSCO, only that Indian sites holding EU, UK, US, Australian or PAHO level-4 registrations, or WHO-prequalified products, pass the gate routinely.
The mechanics are worth stating exactly, because they are unlike the CTD-driven regimes elsewhere in this series. Submission is on Form C in four dossiers — administrative, chemical, clinical including bioequivalence, and manufacturing and packaging — in duplicate, electronic since 4 November 2022 with a hard-copy administrative folder of original or apostilled certificates presented by appointment. The fee is TT$750 per drug and TT$100 per variation. The Regulations require the Minister, on the Drug Advisory Committee's recommendation, to notify within 120 days of filing. Stability must cover at least three lots, accelerated and long-term, for climatic Zone IVb; three finished samples are required, and the two Division documents disagree on whether samples of the active ingredient are needed, so we report both. Labels and inserts are in English and parenterals must carry the lot number. No validity period or renewal was found: a notice of approval stands until withdrawn by Gazette. Antibiotics are carved out to the Antibiotics Act, Chapter 30:02, which we did not read, so injectable antibiotics may follow a different route. Whether a local agent is legally mandatory we could not establish; the Regulations allow the manufacturer or the importer to file, the practice is importer-led, and the CRS notes that the national stage requires an importer or distributor to be identified.
Quality Systems Behind Every Injectable Supplied to Trinidad and Tobago
For a sterile injectable the evidence an assessor expects is the same: aseptic process simulation records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity — the Division specifically asks for the sterility of container surfaces — sterility and bacterial endotoxin testing by LAL, particulate matter, validated HPLC and GC assay and impurity methods, a process description down to lyophilisation where applicable, and ICH Q1A and Q1B stability generated for Zone IVb rather than extrapolated from a temperate zone. Because the Act lets customs inspectors sample and hold a consignment pending an analyst's report, the certificate of analysis and methods for each batch should be written to be reproduced by an outside laboratory.
The international layers are quickly stated. Trinidad and Tobago does not appear on the WHO's August 2026 list of authorities at maturity level 3 or 4, and no published benchmarking result for it was found; India's CDSCO appears on that list for vaccines only. Neither country is a PIC/S participating authority. The founding Act of 1960 has not been superseded, and we found no bill to create a standalone drug regulatory authority, so we do not report one. The one India-specific gate that has opened is on the standards side: during the Prime Minister of India's state visit on 3 and 4 July 2025 the two governments signed a memorandum on pharmacopoeial cooperation under which Trinidad and Tobago recognises the Indian Pharmacopoeia for the quality standards of medicines, and the country appears on the Indian Pharmacopoeia Commission's recognition list of 10 July 2026. That is compendial recognition, not regulatory reliance; we found no amendment to the Regulations giving the IP legal standing, and it does not change the CPP requirement.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in Trinidad and Tobago for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries, including English-speaking markets in the Caribbean and Latin America. We build dossiers in CTD and ACTD format and remap them without loss to the Division's four-section Form C structure, and we supply the WHO-format certificate of a pharmaceutical product, the manufacturing licence and the GMP certificate as a matter of course. Because the certificate-origin test is the gate, we tell buyers plainly which of our products carry a listed-authority CPP or WHO prequalification and which do not, and we work through a registered importer in Port of Spain who files, identifies the distributor, and registers with NIPDEC as a supplier.
The bilateral relationship is deep and, since July 2025, unusually specific about medicines. The Ministry of External Affairs brief of June 2025 records bilateral trade of USD 341.61 million in 2024–25, with Indian exports of USD 120.65 million and imports of USD 220.96 million, after a record USD 368.96 million the year before, and names pharmaceutical products among India's principal exports beside vehicles, iron and steel and plastics; the brief adds that much trade moves indirectly through North America and Europe. UN Comtrade's public preview puts Indian pharmaceutical exports to Trinidad and Tobago at about USD 23.3 million in 2024 and USD 18.9 million in 2025. The health instruments are a memorandum on traditional medicine of 2012, an Ayurveda chair and a medicinal-plants memorandum with the University of the West Indies, and, from the July 2025 state visit, the Indian Pharmacopoeia memorandum, a gift of twenty haemodialysis units and two sea ambulances, 'Heal in India' treatment, and overseas-citizen eligibility extended to the sixth generation of a diaspora the two MEA briefs put at 42% and 40–45% of the population. The joint statement records the Indian Prime Minister commending the recognition of the Indian Pharmacopoeia as a step to 'quality and affordable generic medicines from India'. We found no line of credit.
Where the money is: Trinidad and Tobago has 1.37 million people, gross national income per capita of USD 18,550 in 2025, down for three consecutive years, current health expenditure of about USD 1,276 per person and 7.5% of GDP in 2023, and life expectancy of 73.6 years. Out-of-pocket payments were 45.3% of health expenditure in 2023, diabetes prevalence among adults was 12.4% in 2024, tuberculosis incidence has risen to 27 per 100,000, and the last official renal figure we found put 1,187 patients on renal replacement therapy in May 2018, about 875 per million, with no national registry since. The public buyer is NIPDEC, a subsidiary of the National Insurance Board contracted since October 1993 to run the health supply chain from its central stores at Chaguaramas for the Ministry of Health and the North West, North Central, Eastern, South West and Tobago regional health authorities, and since February 2003 the Chronic Disease Assistance Programme, whose basket of fifty-one items for eleven non-communicable diseases is dispensed free through 275 private pharmacies, figures NIPDEC's own pages give inconsistently, another stating fifty-three items and about 257 dispensing points. NIPDEC registers suppliers on a procurement form, tenders through an electronic portal and, unusually, publishes its award list: the 2025–26 pharmaceutical awards run to 1,458 lines, of which by our approximate count about 48% are Indian-made, rising to about 59% of the 409 injectable lines — dialysis solutions, oncology, insulins and biosimilars, anaesthesia and intensive-care injectables — from Neon, SG Pharma, Getwell, Gland, Dr Reddy's, Venus, Troikaa, Sun, Intas and Biocon among others. Private distribution is concentrated in Agostini's, which owns Smith Robertson and the SuperPharm chain and bought the Aventa group in June 2024, and in Bryden pi. Press reports in May 2026 described programme shortages that the Ministry denied and the pharmacists' society attributed in part to supplier-payment delays; we report both.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is India on Trinidad and Tobago's list of recognised regulatory authorities?
No, on any of the three layers. The Regulations name Canada, the US FDA, the UK and Australia plus a ministerial-discretion clause; the CFDD notice of November 2022 names the WHO stringent authorities for biologics and six PAHO level-4 authorities, the EU-27 and the UK for small molecules and generics; the CRS lists PAHO reference authorities and ICH or WHO level-3 agencies, and CDSCO's level-3 status covers vaccines only. The gate is the origin of the CPP, not the location of the factory: India tops the register every year from 2022 to 2025. We neither claim nor deny that a CDSCO-only CPP would be accepted; no text answers that.
What law governs medicine registration in Trinidad and Tobago?
The Food and Drugs Act, Chapter 30:01 of 1960, last amended by Act 6 of 2005 and not superseded, with the Food and Drugs Regulations of 1964, administered by the Chemistry, Food and Drugs Division of the Ministry of Health with a Drug Advisory Committee. A new drug needs a Form C submission in four sections, an apostilled CPP or free-sale certificate, a GMP certificate from the manufacturing country's regulator, Zone IVb stability on three lots, three samples and TT$750; the Minister must notify within 120 days. No validity period was found; antibiotics fall under the separate Antibiotics Act, Chapter 30:02.
Does the Indian Pharmacopoeia memorandum of July 2025 change the registration route?
Not as far as we can verify. The memorandum, signed during the Indian Prime Minister's state visit on 3 and 4 July 2025, commits Trinidad and Tobago to recognise the Indian Pharmacopoeia for the quality standards of medicines, and the country is on the Indian Pharmacopoeia Commission's July 2026 recognition list. That is recognition of a compendium, not reliance on a regulator: we found no amendment to the Regulations giving the IP legal standing and nothing that alters the reference-authority CPP requirement. It is nonetheless the only India-specific opening in this market, and it is real.
Who buys injectables in Trinidad and Tobago?
NIPDEC, the National Insurance Board subsidiary contracted since 1993 to supply the Ministry of Health and the five regional health authorities and to run the Chronic Disease Assistance Programme, buying under the Public Procurement and Disposal of Public Property Act 2015 through registered suppliers and an electronic tender portal; its 2025–26 award list sources about three fifths of its injectable lines from India. Private demand, where out-of-pocket payments are 45.3% of health spending, runs mainly through Agostini's Smith Robertson and SuperPharm businesses and through Bryden pi, and through private hospitals such as St Clair, Westshore and Medical Associates.
Does Farbe Firma have experience with Caribbean and CARICOM markets?
Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries, including English-speaking Caribbean and Latin American markets. We prepare dossiers in CTD and ACTD format and remap them to the Division's Form C structure, generate Zone IVb stability, supply the WHO-format CPP, manufacturing licence and GMP certificate, and work through registered local importers. Write to director@farbefirma.org with the product list and we will tell you, product by product, which certificate route applies.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments